Clinical Trial Update: Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating simultaneous hyperpolarized [1-13C]pyruvate and 18F-FDG PET/MRS in cancer patients is currently enrolling by invitation acro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Lymphoma
• Neuroendocrine Carcinoma
• Neuroendocrine Tumor
• Sarcoma

Drugs mentioned

• 18F-FDG (fluorodeoxyglucose F-18)
• Hyperpolarized [1-13C]pyruvate (pyruvate (hyperpolarized with carbon-13))

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Breast Cancer, Neuroendocrine Tumors | Phase 2 | Status: ENROLLING_BY_INVITATION